1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Verdone, G. Corazza, A. Viglino, P. Pettirossi, F. Giorgetti, S. Mangione, P. Andreola, A. Stoppini, M. Bellotti, V. Esposito, G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Protein Sci. PRCIEI 0795 0961-8368 11 487 499 10.1110/ps.29002 11847272 The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. 2002 US Protein Sci. PRCIEI 0795 0961-8368 9 831 845 Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation 2000 IX Eur.J.Biochem. EJBCAI 0262 0014-2956 258 61 67 10.1046/j.1432-1327.1998.2580061.x Beta2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. 1998 10.2210/pdb1jnj/pdb pdb_00001jnj 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 11879.356 beta2-microglobulin 1 man polymer no no MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYA CRVNHVTLSQPKIVKWDRDM MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYA CRVNHVTLSQPKIVKWDRDM A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia Escherichia coli sample B2M 9606 Homo sapiens 469008 Escherichia coli BL21(DE3) BL21DE3 PLASMID pHN1 database_2 pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2002-02-27 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model _struct_ref_seq_dif.details X-ray structure at 2.6 A resolution of the HLA-A2 (human histocompatibility antigen) of alfa1, alfa2, alfa3 and beta2-microglobulin domains. X-ray structure at 3.5 A resolution of the HLA-A2 (human histocompatibility antigen) of alfa1, alfa2, alfa3 and beta2-microglobulin domains. RCSB Y RCSB 2001-07-24 REL REL This structure was determined using standard 2D homonuclear techniques target function 380 20 2D_NOESY 2D_NOESY 100 mM NaCl, 70 mM phosphate buffer 6.4 ambient 310 K 100 mM NaCl, 70 mM phosphate buffer 6.4 ambient 310 K the structures are based on a total of 1608 restraints, 1541 are NOE-derived distance contraints, 67 dihedral angle restraints simulated annealing, restrained molecular dynamics, restrained molecular mechanics 0.68 mM beta2-m; 70 mM phosphate buffer NA, 100 mM NaCl. 90% H2O/10% D2O 0.37 mM beta2-m; 70 mM phosphate buffer NA, 100 mM NaCl. 100% D2O Bruker collection XwinNMR 2.6 MSI processing Felix 2000 MSI data analysis Felix 2000 Guentert structure solution DIANA 1.5 MSI refinement Discover 2000 500 Bruker AVANCE MET 0 n 1 MET 0 A ILE 1 n 2 ILE 1 A GLN 2 n 3 GLN 2 A ARG 3 n 4 ARG 3 A THR 4 n 5 THR 4 A PRO 5 n 6 PRO 5 A LYS 6 n 7 LYS 6 A ILE 7 n 8 ILE 7 A GLN 8 n 9 GLN 8 A VAL 9 n 10 VAL 9 A TYR 10 n 11 TYR 10 A SER 11 n 12 SER 11 A ARG 12 n 13 ARG 12 A HIS 13 n 14 HIS 13 A PRO 14 n 15 PRO 14 A ALA 15 n 16 ALA 15 A GLU 16 n 17 GLU 16 A ASN 17 n 18 ASN 17 A GLY 18 n 19 GLY 18 A LYS 19 n 20 LYS 19 A SER 20 n 21 SER 20 A ASN 21 n 22 ASN 21 A PHE 22 n 23 PHE 22 A LEU 23 n 24 LEU 23 A ASN 24 n 25 ASN 24 A CYS 25 n 26 CYS 25 A TYR 26 n 27 TYR 26 A VAL 27 n 28 VAL 27 A SER 28 n 29 SER 28 A GLY 29 n 30 GLY 29 A PHE 30 n 31 PHE 30 A HIS 31 n 32 HIS 31 A PRO 32 n 33 PRO 32 A SER 33 n 34 SER 33 A ASP 34 n 35 ASP 34 A ILE 35 n 36 ILE 35 A GLU 36 n 37 GLU 36 A VAL 37 n 38 VAL 37 A ASP 38 n 39 ASP 38 A LEU 39 n 40 LEU 39 A LEU 40 n 41 LEU 40 A LYS 41 n 42 LYS 41 A ASN 42 n 43 ASN 42 A GLY 43 n 44 GLY 43 A GLU 44 n 45 GLU 44 A ARG 45 n 46 ARG 45 A ILE 46 n 47 ILE 46 A GLU 47 n 48 GLU 47 A LYS 48 n 49 LYS 48 A VAL 49 n 50 VAL 49 A GLU 50 n 51 GLU 50 A HIS 51 n 52 HIS 51 A SER 52 n 53 SER 52 A ASP 53 n 54 ASP 53 A LEU 54 n 55 LEU 54 A SER 55 n 56 SER 55 A PHE 56 n 57 PHE 56 A SER 57 n 58 SER 57 A LYS 58 n 59 LYS 58 A ASP 59 n 60 ASP 59 A TRP 60 n 61 TRP 60 A SER 61 n 62 SER 61 A PHE 62 n 63 PHE 62 A TYR 63 n 64 TYR 63 A LEU 64 n 65 LEU 64 A LEU 65 n 66 LEU 65 A TYR 66 n 67 TYR 66 A TYR 67 n 68 TYR 67 A THR 68 n 69 THR 68 A GLU 69 n 70 GLU 69 A PHE 70 n 71 PHE 70 A THR 71 n 72 THR 71 A PRO 72 n 73 PRO 72 A THR 73 n 74 THR 73 A GLU 74 n 75 GLU 74 A LYS 75 n 76 LYS 75 A ASP 76 n 77 ASP 76 A GLU 77 n 78 GLU 77 A TYR 78 n 79 TYR 78 A ALA 79 n 80 ALA 79 A CYS 80 n 81 CYS 80 A ARG 81 n 82 ARG 81 A VAL 82 n 83 VAL 82 A ASN 83 n 84 ASN 83 A HIS 84 n 85 HIS 84 A VAL 85 n 86 VAL 85 A THR 86 n 87 THR 86 A LEU 87 n 88 LEU 87 A SER 88 n 89 SER 88 A GLN 89 n 90 GLN 89 A PRO 90 n 91 PRO 90 A LYS 91 n 92 LYS 91 A ILE 92 n 93 ILE 92 A VAL 93 n 94 VAL 93 A LYS 94 n 95 LYS 94 A TRP 95 n 96 TRP 95 A ASP 96 n 97 ASP 96 A ARG 97 n 98 ARG 97 A ASP 98 n 99 ASP 98 A MET 99 n 100 MET 99 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N LYS 6 A N LYS 7 A O SER 28 A O SER 29 A N CYS 25 A N CYS 26 A O TYR 66 A O TYR 67 A O TYR 67 A O TYR 68 A N GLU 50 A N GLU 51 A O LYS 91 A O LYS 92 A N VAL 82 A N VAL 83 A O ASN 83 A O ASN 84 A N GLU 36 A N GLU 37 A O LYS 91 A O LYS 92 A N VAL 82 A N VAL 83 A O ALA 79 A O ALA 80 A N LEU 40 A N LEU 41 A N LEU 39 A N LEU 40 A O ILE 46 A O ILE 47 5 A A SER LYS 57 58 -143.50 13 A A SER LYS 57 58 -134.62 1 A TYR 26 0.066 SIDE CHAIN 1 A TYR 63 0.085 SIDE CHAIN 1 A TYR 66 0.177 SIDE CHAIN 2 A TYR 63 0.076 SIDE CHAIN 2 A TYR 66 0.203 SIDE CHAIN 3 A TYR 66 0.213 SIDE CHAIN 4 A TYR 63 0.116 SIDE CHAIN 4 A TYR 66 0.181 SIDE CHAIN 4 A TYR 67 0.104 SIDE CHAIN 5 A PHE 30 0.132 SIDE CHAIN 5 A TYR 63 0.166 SIDE CHAIN 5 A TYR 66 0.231 SIDE CHAIN 5 A TYR 67 0.064 SIDE CHAIN 6 A TYR 63 0.069 SIDE CHAIN 6 A TYR 66 0.207 SIDE CHAIN 7 A TYR 26 0.072 SIDE CHAIN 7 A TYR 66 0.185 SIDE CHAIN 8 A TYR 63 0.089 SIDE CHAIN 8 A TYR 66 0.189 SIDE CHAIN 9 A TYR 10 0.087 SIDE CHAIN 9 A TYR 66 0.206 SIDE CHAIN 10 A PHE 30 0.080 SIDE CHAIN 10 A TYR 66 0.174 SIDE CHAIN 10 A TYR 67 0.074 SIDE CHAIN 11 A TYR 66 0.180 SIDE CHAIN 11 A TYR 67 0.093 SIDE CHAIN 12 A PHE 62 0.085 SIDE CHAIN 12 A TYR 66 0.200 SIDE CHAIN 12 A TYR 67 0.108 SIDE CHAIN 13 A TYR 63 0.106 SIDE CHAIN 13 A TYR 66 0.200 SIDE CHAIN 13 A TYR 67 0.072 SIDE CHAIN 14 A PHE 30 0.108 SIDE CHAIN 14 A TYR 63 0.088 SIDE CHAIN 14 A TYR 66 0.197 SIDE CHAIN 15 A TYR 66 0.191 SIDE CHAIN 16 A TYR 66 0.262 SIDE CHAIN 17 A TYR 63 0.082 SIDE CHAIN 17 A TYR 66 0.188 SIDE CHAIN 18 A TYR 63 0.106 SIDE CHAIN 18 A TYR 66 0.185 SIDE CHAIN 18 A PHE 70 0.188 SIDE CHAIN 18 A TYR 78 0.070 SIDE CHAIN 19 A TYR 26 0.083 SIDE CHAIN 19 A TYR 63 0.075 SIDE CHAIN 19 A TYR 66 0.170 SIDE CHAIN 19 A PHE 70 0.145 SIDE CHAIN 20 A TYR 63 0.077 SIDE CHAIN 20 A TYR 66 0.193 SIDE CHAIN 20 A PHE 70 0.091 SIDE CHAIN 20 A ARG 97 0.091 SIDE CHAIN 5 -4.39 0.60 121.00 116.61 A A A CB CG CD1 TYR TYR TYR 63 63 63 N 18 -3.69 0.60 121.00 117.31 A A A CB CG CD1 TYR TYR TYR 63 63 63 N 1 A GLN 2 -114.15 71.96 1 A ASN 21 -118.32 -147.85 1 A LYS 41 -81.91 -133.08 1 A ASP 53 66.29 170.69 1 A SER 57 52.81 19.29 1 A LYS 58 21.71 41.75 1 A ASP 59 -108.44 -109.72 1 A GLU 74 55.62 -93.72 1 A ASN 83 -151.91 76.08 1 A TRP 95 -62.97 -86.13 1 A ASP 96 165.54 177.87 2 A ILE 1 -144.73 13.04 2 A ASN 21 -127.51 -154.35 2 A HIS 31 -174.85 143.81 2 A PRO 32 -85.43 -151.74 2 A LYS 41 -79.07 -140.55 2 A SER 55 -113.97 64.12 2 A ASP 59 -66.96 -85.57 2 A TRP 60 -172.20 63.81 2 A GLU 74 43.41 -100.71 2 A SER 88 71.99 -41.71 2 A TRP 95 -76.94 -98.71 2 A ASP 96 170.69 -171.94 2 A ARG 97 -160.90 -61.92 2 A ASP 98 -154.93 62.24 3 A ILE 1 -56.54 173.62 3 A ALA 15 64.14 141.98 3 A ASN 21 -120.63 -149.73 3 A HIS 31 -171.75 145.16 3 A PRO 32 -87.31 -149.43 3 A LYS 41 -79.60 -138.78 3 A SER 57 51.64 -150.44 3 A PHE 62 -170.54 124.54 3 A GLU 74 59.68 -93.51 3 A SER 88 72.45 -38.94 3 A LYS 94 43.11 85.67 3 A TRP 95 -31.93 111.18 4 A ALA 15 59.02 -175.27 4 A GLU 16 -167.85 -162.21 4 A ASN 21 -114.74 -145.55 4 A HIS 31 -171.53 148.14 4 A PRO 32 -84.17 -158.29 4 A LYS 41 -82.16 -142.23 4 A ASP 53 -8.51 -78.30 4 A LYS 58 24.76 41.87 4 A GLU 74 59.84 -91.87 4 A SER 88 75.08 -43.00 4 A ARG 97 -14.60 -83.90 5 A ASN 21 -115.94 -139.99 5 A LYS 41 -85.06 -142.01 5 A GLU 47 -108.97 41.31 5 A SER 52 -70.92 -134.12 5 A ASP 53 -154.68 41.25 5 A LEU 54 67.04 116.98 5 A PHE 56 -68.00 3.45 5 A LYS 58 -43.32 62.01 5 A GLU 69 -109.36 74.28 5 A GLU 74 60.76 -82.72 5 A SER 88 72.20 -43.05 6 A ASN 21 -123.63 -144.06 6 A PRO 32 -91.80 -149.83 6 A LYS 41 -81.73 -138.48 6 A SER 55 -104.40 64.25 6 A ASP 59 -81.46 45.46 6 A TRP 60 46.16 81.14 6 A LEU 64 -171.42 144.44 6 A GLU 74 60.63 -96.49 6 A TRP 95 -74.82 -88.14 6 A ASP 96 173.90 -162.40 7 A ASN 21 -115.18 -150.56 7 A PHE 30 -62.30 -178.47 7 A HIS 31 173.05 124.82 7 A PRO 32 -86.26 -142.85 7 A LYS 41 -81.51 -136.75 7 A SER 57 57.99 129.66 7 A ASP 59 -77.16 24.77 7 A TRP 60 64.14 84.67 7 A ARG 97 -97.99 -128.05 8 A ILE 1 -89.40 45.56 8 A GLN 2 -108.70 72.03 8 A ALA 15 64.14 162.09 8 A ASN 17 -52.89 105.99 8 A LYS 41 -78.93 -138.23 8 A ASP 53 72.70 178.54 8 A LYS 58 18.41 44.35 8 A ASP 59 -118.51 -166.20 8 A GLU 74 68.73 -72.41 8 A LYS 75 -97.95 48.05 9 A ALA 15 62.69 155.55 9 A ASN 21 -119.01 -146.40 9 A PRO 32 -89.44 -143.96 9 A LYS 41 -86.03 -128.36 9 A GLU 50 -90.24 58.65 9 A GLU 74 55.71 -120.51 9 A LYS 75 -86.54 49.47 10 A ASN 21 -116.27 -150.23 10 A LYS 41 -82.30 -132.17 10 A SER 57 59.23 147.91 10 A PHE 62 -13.23 118.62 10 A GLU 74 52.15 -94.13 10 A THR 86 -175.08 -42.55 10 A ASP 96 -98.52 33.07 10 A ARG 97 54.00 82.44 11 A ILE 1 73.23 -61.25 11 A ASN 21 -117.39 -167.28 11 A HIS 31 -171.57 149.67 11 A PRO 32 -88.22 -133.34 11 A LYS 41 -81.83 -137.43 11 A GLU 50 -92.89 58.74 11 A ASP 53 58.78 -173.02 11 A ASP 59 -74.19 -91.15 11 A TRP 60 -164.73 70.09 11 A THR 73 -66.05 99.72 11 A GLU 74 53.85 -92.07 11 A SER 88 71.15 -32.17 11 A ARG 97 53.32 81.32 11 A ASP 98 58.18 84.28 12 A ASN 21 -134.11 -147.03 12 A SER 33 -79.56 34.44 12 A LYS 41 -82.05 -138.23 12 A GLU 47 -72.99 -80.35 12 A SER 57 -78.00 -121.07 12 A ASP 59 -94.48 44.53 12 A THR 73 -87.89 -153.47 12 A GLU 74 -67.01 -72.24 12 A LYS 75 -116.35 50.98 12 A ARG 97 -95.73 -131.91 12 A ASP 98 -119.82 65.81 13 A ALA 15 59.01 -175.48 13 A GLU 16 -164.88 -149.30 13 A ASN 21 -121.33 -147.86 13 A PRO 32 -83.33 -157.13 13 A LYS 41 -78.63 -131.35 13 A ASP 53 -65.08 -78.91 13 A LEU 54 -161.96 119.71 13 A PHE 56 -80.51 31.83 13 A LYS 58 -17.85 50.35 13 A ASP 59 -119.70 -72.57 13 A TRP 60 -158.37 -46.78 13 A SER 61 -60.10 98.56 13 A SER 88 -80.46 41.33 13 A GLN 89 -171.56 137.48 14 A PRO 14 -86.23 45.72 14 A ALA 15 67.46 140.38 14 A GLU 16 -166.70 108.58 14 A ASN 21 -108.30 -157.00 14 A LYS 41 -88.39 -124.19 14 A ASP 53 69.67 168.95 14 A SER 57 35.80 40.53 14 A LYS 58 11.91 45.19 14 A ASP 59 -108.62 -162.35 14 A TRP 60 -96.69 34.69 14 A PHE 62 -161.20 112.80 14 A GLU 69 -114.96 72.92 14 A GLU 74 60.06 -96.88 14 A ARG 97 49.76 94.65 15 A LYS 41 -82.76 -136.33 15 A ASP 53 68.09 159.18 15 A TRP 60 62.44 60.41 15 A LEU 64 -174.85 149.70 15 A GLU 69 -112.93 70.28 15 A LYS 75 -96.14 56.89 15 A TRP 95 -58.36 -83.60 15 A ASP 96 172.70 -166.84 15 A ARG 97 -157.77 78.30 15 A ASP 98 -113.74 78.32 16 A SER 20 -37.88 128.00 16 A ASN 21 -122.12 -143.63 16 A SER 33 -77.64 21.44 16 A LYS 41 -82.63 -135.48 16 A ASP 53 69.84 164.36 16 A SER 57 54.78 -151.13 16 A ASP 59 -95.99 -101.31 16 A TRP 60 -163.45 5.95 16 A SER 61 -83.34 -147.66 16 A PHE 62 -175.64 127.79 16 A GLU 74 62.59 -80.99 16 A SER 88 75.96 -45.77 16 A ARG 97 -149.17 -128.09 17 A ALA 15 69.63 132.25 17 A ASN 21 -111.33 -141.48 17 A HIS 31 -178.35 141.89 17 A PRO 32 -89.03 -144.13 17 A LYS 41 -81.37 -137.89 17 A LEU 54 69.19 112.26 17 A SER 57 55.44 -173.17 17 A ASP 59 -95.67 39.61 17 A SER 61 -106.35 -161.97 17 A GLU 74 47.42 -121.13 17 A ARG 97 -53.99 -83.39 17 A ASP 98 -172.25 67.01 18 A ASN 17 -53.85 106.87 18 A ASN 21 -97.78 -147.77 18 A PRO 32 -89.84 -121.05 18 A LYS 41 -75.58 -139.63 18 A GLU 47 -71.13 -75.68 18 A SER 57 51.54 -147.68 18 A ASP 59 -86.37 45.59 18 A LYS 75 -100.14 51.54 18 A GLU 77 -144.85 53.21 18 A ASP 98 -141.91 -57.26 19 A ASN 21 -122.83 -143.98 19 A HIS 31 -171.53 149.88 19 A PRO 32 -83.27 -146.69 19 A LYS 41 -85.97 -132.29 19 A GLU 47 -86.72 49.59 19 A ASP 53 51.21 -145.41 19 A LYS 58 26.96 45.31 19 A SER 61 -66.51 -175.24 19 A GLU 74 56.19 -99.94 19 A GLU 77 -101.63 69.04 20 A ARG 12 -116.43 -85.47 20 A PRO 14 -79.52 47.09 20 A ALA 15 57.09 100.55 20 A LYS 19 -68.57 84.61 20 A ASN 21 -120.29 -152.46 20 A HIS 31 -171.35 142.82 20 A PRO 32 -91.81 -137.65 20 A LYS 41 -80.75 -139.80 20 A SER 57 48.95 -152.93 20 A ASP 59 -87.95 48.50 20 A TRP 60 58.08 17.06 20 A GLU 77 -154.74 58.17 20 A SER 88 72.04 -35.97 NMR solution structure of the human beta2-microglobulin 1 N N disulf 2.055 A CYS 25 A SG CYS 26 1_555 A CYS 80 A SG CYS 81 1_555 IMMUNE SYSTEM immunoglobulin constant domain, IMMUNE SYSTEM A HIS 31 A HIS 32 1 A PRO 32 A PRO 33 11.35 A HIS 31 A HIS 32 2 A PRO 32 A PRO 33 7.32 A HIS 31 A HIS 32 3 A PRO 32 A PRO 33 8.09 A HIS 31 A HIS 32 4 A PRO 32 A PRO 33 4.12 A HIS 31 A HIS 32 5 A PRO 32 A PRO 33 6.05 A HIS 31 A HIS 32 6 A PRO 32 A PRO 33 6.81 A HIS 31 A HIS 32 7 A PRO 32 A PRO 33 7.13 A HIS 31 A HIS 32 8 A PRO 32 A PRO 33 8.88 A HIS 31 A HIS 32 9 A PRO 32 A PRO 33 1.27 A HIS 31 A HIS 32 10 A PRO 32 A PRO 33 6.88 A HIS 31 A HIS 32 11 A PRO 32 A PRO 33 1.29 A HIS 31 A HIS 32 12 A PRO 32 A PRO 33 13.08 A HIS 31 A HIS 32 13 A PRO 32 A PRO 33 0.14 A HIS 31 A HIS 32 14 A PRO 32 A PRO 33 13.17 A HIS 31 A HIS 32 15 A PRO 32 A PRO 33 9.77 A HIS 31 A HIS 32 16 A PRO 32 A PRO 33 9.68 A HIS 31 A HIS 32 17 A PRO 32 A PRO 33 9.14 A HIS 31 A HIS 32 18 A PRO 32 A PRO 33 0.26 A HIS 31 A HIS 32 19 A PRO 32 A PRO 33 1.48 A HIS 31 A HIS 32 20 A PRO 32 A PRO 33 9.11 B2MG_HUMAN UNP 1 21 P61769 IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAC RVNHVTLSQPKIVKWDRDM 21 119 1JNJ 1 99 P61769 A 1 2 100 1 cloning artifact MET 0 1JNJ A P61769 UNP 1 4 3 4 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A LYS 6 A LYS 7 A SER 11 A SER 12 A LEU 23 A LEU 24 A SER 28 A SER 29 A LEU 64 A LEU 65 A THR 68 A THR 69 A GLU 50 A GLU 51 A HIS 51 A HIS 52 A LYS 91 A LYS 92 A LYS 94 A LYS 95 A ALA 79 A ALA 80 A HIS 84 A HIS 85 A ILE 35 A ILE 36 A GLU 36 A GLU 37 A LYS 91 A LYS 92 A LYS 94 A LYS 95 A ALA 79 A ALA 80 A HIS 84 A HIS 85 A LEU 39 A LEU 40 A LEU 40 A LEU 41 A ARG 45 A ARG 46 A ILE 46 A ILE 47